Zurn Elkay raises 2025 guidance with 5%+ core sales growth and $420M–$430M EBITDA outlook amid robust Q2 results Zurn Elkay raises 2025 guidance with 5%+ core sales growth and $420M–$430M EBITDA outlook amid robust Q2 results Post ContentzwsRead More You might also be interested in reading Biggest stock movers Tuesday: MEDP, NXPI, and more. July 30, 2025 In Mainstream ← Previous post Next post →